GCCP Dermatology — Master Overview | Internal

§ 0 · Executive summary

A market mapped end-to-end — from sole-consultant chambers to multi-billion institutional flagship.

By the time a partner finishes this document they will understand the full operating spectrum from €100k chambers to €50m+ Mohs flagship, the three clinical sub-specialty divisions cutting across every tier, and a transparent data-driven scoring of which cell offers GCCP the most attractive risk-adjusted return.

— 01

Cosmetic dominates the scoring at every tier.

Highest-margin cash-pay revenue + scalable + lighter regulatory burden than surgical-Mohs + strong capital efficiency. The instinct toward Mohs flagship as the "gold standard" is correct on prestige but wrong on risk-adjusted return at GCCP's capital and time-budget envelope.

— 02

Consultant supply is the binding constraint at every tier.

Ireland produces 3–4 dermatology CCT-holding consultants per year. POCC23 (effective January 2026) prohibits on-site private practice for new public-only contract holders, intensifying the squeeze. No financial model survives a consultant-supply failure.

— 03

Scoring is a guide, not a recommendation.

The data-driven scoring shows T2-B Cosmetic Boutique with medical mix at 78.4 / 100 as the optimal cell. Partners can flex weights to test sensitivity. The tier-migration paths in §11 show how to layer toward Tier 3 over 3–5 years.

The nine cells · scored

Three tiers × three clinical divisions = nine cells.

Division A · Medical

Division B · Cosmetic

Division C · Surgical / Skin Cancer

Tier 1
€100k–€1m

63.4

T1-A

Chambers · sessional consultant

Capex €350k · Y5 EBITDA €187k

68.1

T1-B

Chambers + 1 device

Capex €400k · Y5 EBITDA €255k

46.8

T1-C

Screening only · no Mohs

Capex €450k · Y5 EBITDA €126k

Tier 2
€500k–€4m

69.7

T2-A

Boutique medical-led

Capex €1.8m · Y5 EBITDA €1.49m

78.4

T2-B

Boutique cosmetic + medical mix

Capex €2.0m · Y5 EBITDA €1.91m

65.1

T2-C

Day-surgery + TBI · no Mohs

Capex €2.5m · Y5 EBITDA €1.71m

Tier 3
€8m–€50m+

60.2

T3-A

Multi-site GP-referrer platform

Capex €18m · Y5 EBITDA €5.92m

78.2

T3-B

Premium hub + skin-clinics chain

Capex €15m · Y5 EBITDA €7.70m

51.0

T3-C

Mohs flagship + biologics + paeds

Capex €40m · Y5 EBITDA €7.20m

— Rank 01

T2-B

Tier 2 Cosmetic Boutique with medical mix

78.4/ 100

Capex (mid)€2.0m

Y5 revenue€5.8m

Y5 EBITDA€1.91m · 33%

Y5 EV (mid)€20.1m

EV / Capex11.0× · highest in matrix

— Rank 02

T3-B

Tier 3 Cosmetic Premium Hub + Skin-Clinics Chain

78.2/ 100

Capex (mid)€15m

Y5 revenue€22m

Y5 EBITDA€7.70m · 35%

Y5 EV (mid)€92m

EV / Capex6.1×

— Rank 03

T2-A

Tier 2 Medical Boutique

69.7/ 100

Capex (mid)€1.8m

Y5 revenue€5.5m

Y5 EBITDA€1.49m · 27%

Y5 EV (mid)€16m

EV / Capex8.9×

§ 1 · National market context

Demand is structurally large and growing on every measurable axis.

Sixty thousand patients on a public dermatology waiting list. Eleven thousand new skin-cancer diagnoses per year. A €42m aesthetic market growing at 10.74% CAGR. And only fifty-four consultants to serve them.

Demand structure

60k+

on public WL · June 2025

370k

projected WL by 2035

11k

new skin cancers / yr

€42m

aesthetic market 2024

Three demand flows compose the addressable market.

— Skin cancer is the fastest-growing pipeline. NMSC incidence is projected to increase 177–189% between 2015 and 2045 driven by population ageing. Stage IV melanoma costs €122,985 to treat versus €4,269 for Stage IA — a 29× cost differential creating a clinical and payer incentive for early private detection.

— Inflammatory disease is the recurring revenue base. 54% of the Irish population is affected by skin disease annually. Eczema affects one in five children. Psoriasis generates 6,167 new diagnoses per year.

— Cosmetic / aesthetic is the cash-pay engine. Growing at 10.74% CAGR. Male patients now account for 20–25% of bookings — meaningful demographic expansion.

Supply structure — the binding constraint.

Ireland's dermatology workforce is the binding constraint at every tier of this market. 50–55 WTE consultant dermatologists nationally. 84% are based in Model 4 hospitals — concentrated in Dublin, Cork, Galway, Limerick.

The HST training pipeline produces 3–4 CCT-holding consultants per year. Australia and the UK both pull. Twelve counties have zero listed private dermatologists.

3–4

CCT consultants / yr · ROI HST output

12

counties with zero listed consultants

46%

national PHI penetration · 2.52m insured

£400k

Belfast Skin Clinic consultant ad · market signal

Insurer landscape · three scenarios.

Three insurers dominate: VHI, Laya (AXA-acquired 2023, €650m, explicit "recapture margin" mandate), and Irish Life Health. GCCP positioning per P4 verified: dual-insurer participating provider with VHI + ILH; keep Laya non-participating to preserve M&A optionality (Laya is the highest-probability acquirer of any GCCP dermatology platform — 45–55% probability).

55%

Base — VHI matches Laya cap by Y2.

Average insurer reimbursement falls €170 → €128 by Y3.

−€350k–€500k EBITDA / centre / yr

30%

Adverse — procedure-bundled rates by Y2–3.

All three insurers coordinate; eliminates per-consultation balance-billing.

−€1.5m–€2.0m EBITDA / centre / yr

15%

Severe — single dominant rate-setter at €110.

Insurer market consolidation drives extreme rate compression.

−€2.5m–€3.5m EBITDA / centre / yr

Public-pathway revenue floors.

NTPF dermatology tender expected Q3–Q4 2026 creates a direct-contract route for GCCP-grade providers. NI Waiting List Reimbursement Scheme (£10m fund, Phase 2 EU-extended Sept 2025) directs NI patients waiting >52 weeks to private ROI providers — 49,048 dermatology patients on NI WL, 8,382 waiting more than four years. No ROI provider has yet established a dedicated dermatology pathway for NI WLRS — first-mover opportunity. Combined NTPF + NI cross-border underwrites 15–25% of revenue floor at every tier on a pricing floor independent of private insurer compression.

§ 2 · The framework

Three operating tiers — and how to read them.

Each tier section is self-contained. A reader can skip to Tier 2 alone and understand the staffing, capex, opex, premises, licensing, revenue, scalability, and risk profile of all three Tier-2 cells without reading Tier 1 or Tier 3.

Tier 1 · €100k–€1m

Entry-Level Operations

Smallest defensible operating footprint. Single consultant or sessional arrangement. Chambers within an existing private hospital, or a standalone clinical suite.

Footprint500–1,500 sqft

FTE per site3–4

Time-to-EBITDA-breakeven6–12 months

Y5 EBITDA€126k–€255k

Tier 2 · €500k–€4m

Mid-Level Boutique

First credibly investable LP product in this market. Single boutique clinic. Multi-payer revenue model. PropCo / OpCo split available where freehold is the route.

Footprint2,500–4,000 sqft

FTE per site10–14

Time-to-EBITDA-breakeven12–18 months

Y5 EBITDA€1.49m–€1.91m

Tier 3 · €8m–€50m+

Institutional Flagship

Multi-site institutional platform. The IoD-equivalent. Full HEPA Mohs theatres, biologics infusion suite, paediatric service line, in-house pathology lab. Insurer-strategic exit at 14× achievable.

Footprint8,000–16,000 sqft

FTE45–60+

Time-to-EBITDA-breakeven18–30 months

Y5 EBITDA€5.92m–€7.70m

Scoring rubric · 100 points

Each cell is scored on seven dimensions, weighted as: Profitability 25 · Scalability 20 · Capital efficiency 15 · OpCo / PropCo capability 15 · Technical complexity inverse 10 · Founder-time burn inverse 10 · Risk-adjusted 5. The Excel companion encodes all scoring formulas; partners can flex weights and observe sensitivity. Default weights are the GCCP partner-assumption defaults.

§ 3 · Tier 1

Small premises.

Chambers or a single suite. One consultant. The proof-it-and-scale entry. Historically how Irish consultant-led dermatology starts — HRBR began inside Blackrock; Beacon Face & Dermatology started inside Beacon Hospital before scaling out.

Capital range

€100k–€1m

Footprint

500–1,500 sqft

FTE per site

3–4 total

Time-to-EBITDA-breakeven

6–12 months

Premises storyboard · five frames

Tier 1 exterior — **Frame 01**Georgian door · brass plate · single suite

Tier 1 reception — **Frame 02**Reception · two chairs, single stem

**Frame 03**Consultation room · 150 sqft

**Frame 04**Treatment · single laser device

63.4

T1-A · Medical

Chambers · sessional consultant

Single anchor consultant performing general medical dermatology, eczema/psoriasis follow-up, GP-referred lesion checks. 700 sqft chambers or 1,000 sqft standalone suite.

Capex (mid)€350k

Y3 EBITDA€126k · 18%

Y5 EBITDA€187k · 22%

EV / Capex5.1×

68.1

T1-B · Cosmetic — Tier 1 winner

Chambers + 1 device

Cosmetic-led entry. Toxin / filler injectables, Vbeam Perfecta or Picosure, skincare retail. RNP-led capable. Highest-margin Tier 1 cell. Lowest single-anchor risk.

Capex (mid)€400k

Y3 EBITDA€189k · 27%

Y5 EBITDA€255k · 30%

EV / Capex5.8×

46.8

T1-C · Surgical

Screening only · no Mohs

Skin-cancer surveillance + dermoscopy + total-body imaging. No Mohs surgery (requires Tier 2/3 sterile theatre). Most operators bundle screening into a Tier 2-A medical boutique.

Capex (mid)€450k

Y5 EBITDA€126k · 18%

EV / Capex2.9×

Lowest score in matrix46.8

T1 sub-variant · The Network of Ten

10× Tier 1 sites + Dublin shared services hub

A single Tier 1 site is a small business at €187–€255k Y5 EBITDA. Ten sites operating under a centralised hub is a different proposition — a multi-region platform with €8.5m Y5 revenue, €1.7m net-of-HQ EBITDA, €17m EV at 10× exit, and 4.5× capital efficiency. Mirrors Schweiger Dermatology Group (US, 170+ locations) and Forefront Dermatology. The network's strength is replicability (19/20 — highest scalability in the matrix); its weakness is the same consultant-supply ceiling as Tier 3 (10 anchors needed). Score: 61.4 / 100.

§ 4 · Tier 2 · Optimal by score

Medium boutique.

A 2,500–4,000 sqft single-site boutique with 2–4 consultants and 10–14 FTE. The first credibly investable LP product. Operating scale of Stratum Dermatology UK and Cadogan Clinic Chelsea.

Capital range

€500k–€4m

Footprint

2,500–4,000 sqft

FTE per site

10–14 total

Time-to-EBITDA-breakeven

12–18 months

Premises storyboard · five frames

Tier 2 exterior — **Frame 01**Edwardian commercial · brass signage

**Frame 02**Reception atrium · double-height

TBI — **Frame 05**Total-body imaging · skin map

69.7

T2-A · Medical

Boutique medical-led

2,500–3,500 sqft. 2–3 consultants. 60% medical / 25% cosmetic / 15% screening. Closest comp: Adare Clinic Limerick.

Capex€1.8m

Y3 EBITDA€924k · 22%

Y5 EBITDA€1.49m · 27%

Y5 EV (mid)€15.6m

78.4

T2-B · Cosmetic + medical · OPTIMAL

Boutique cosmetic + medical mix

Highest score in the matrix. 60% cosmetic / 30% medical / 10% screening. Premium consultant-led. Cadogan Clinic Chelsea is the cleanest international analogue.

Capex€2.0m

Y3 EBITDA€1.35m · 30%

Y5 EBITDA€1.91m · 33%

Y5 EV (mid)€20.1m · EV/Capex 11.0×

65.1

T2-C · Surgical

Day-surgery + TBI · no Mohs

3,000–4,000 sqft. 3 consultants. Day-surgery theatre (not HEPA Mohs). Skin oncology focus. Heavier capex; higher consultant-supply load.

Capex€2.5m

Y3 EBITDA€1.10m · 25%

Y5 EBITDA€1.71m · 30%

EV / Capex7.6×

The decision at Tier 2 · Lease vs Freehold

Lease (€500k–€2m fit-out) preserves capital for second-site expansion; lower IRR but faster scale. Freehold (€2m–€4m all-in) adds Section 110 SPV PropCo gain at SLB Y5 (€7–€8m return-of-capital at 5.5–5.75% NIY); higher overall IRR but ties capital to single asset. The freehold path is recommended where the building is healthcare-consented and below market €/sqft — Park Avenue Sandymount qualifies at €401/sqft and €3.95m freehold healthcare-consented.

Why T2-B wins

T2-B optimises for the seven scoring dimensions simultaneously: high cosmetic margin × scalable model × strong capital efficiency × PropCo capable × moderate regulatory burden × moderate founder-time × low consultant-supply binding (RNP-augmentable). Each individual cell may score higher on one or two dimensions — T3-B beats on absolute scale; T1-A beats on scalability; T1-B beats on founder-time — but T2-B has no major weakness. It is the most robust optimal cell across weight variations: only profit-heavy weighting flips the ranking to T3-B.

§ 5 · Tier 3

State-of-the-art flagship.

The institutional multi-site platform. The IoD-equivalent. The only tier that competes head-on with Institute of Dermatologists Dublin (€11.9m revenue mid; 13 consultants). Most consultant-supply binding. Most founder-time intensive. Largest absolute return.

Capital range

€8m–€50m+

Footprint

8,000–16,000 sqft

Consultants

8–12 platform-wide

Y5 EBITDA

€5.92m – €7.70m

Premises storyboard · five frames

Tier 3 exterior — **Frame 01**Flagship exterior · institutional

**Frame 02**Atrium · monumental staircase

**Frame 04**Biologics infusion · 6 chairs

Pathology lab — **Frame 05**INAB pathology lab · in-house

60.2

T3-A · Medical

Multi-site GP-referrer platform

3 sites · 8–12 consultants · 45 FTE. Strategic moat: GP referrer programme + brand depth + insurer panel dominance. Comparable: The Dermatology Partnership UK (Bupa-acquired Dec 2024).

Capex (mid)€18m

Y5 revenue€18.5m

Y5 EBITDA€5.92m · 32%

Y5 EV (mid)€65m · EV/Capex 3.6×

78.2

T3-B · Cosmetic — Tier 3 winner

Premium hub + skin-clinics chain

1 flagship + 4–6 satellite cosmetic clinics · 50 FTE. Tied at the top with T2-B (78.2 vs 78.4). Highest absolute EBITDA in the matrix. No exact Irish comp at scale.

Capex (mid)€15m

Y5 revenue€22m

Y5 EBITDA€7.70m · 35%

Y5 EV (mid)€92m · EV/Capex 6.1×

51.0

T3-C · Surgical · "Gold Standard"

Mohs flagship + biologics + paeds

Full HEPA Mohs theatres + biologics infusion + paediatric + INAB pathology lab. The IoD-equivalent. Required for insurer-strategic 14× exit (Bridgepoint→Oasis→Bupa template).

Capex (mid)€40m

Y5 revenue€22.5m

Y5 EBITDA€7.20m · 32%

Y5 EV (insurer-strategic)€94m

Why T3-C scores low despite €7.2m Y5 EBITDA

The 100-point rubric penalises capital intensity (T3-C EV/Capex 1.9× vs T2-B's 11.0×), regulatory complexity (12 regulator touchpoints vs T1-B's 2), and founder-time burn (16 days/month vs 1.5). These are real risk factors, not artefacts of the scoring. T3-C delivers the highest absolute EBITDA but at the worst risk-adjusted return.

T3-C remains the only viable cell for insurer-strategic exit at 14× multiple — the Bridgepoint→Oasis Dental→Bupa template requires Mohs surgical capability + biologics infusion + multi-site to access the insurer M&A pool. If the strategic objective is maximum exit value (€100m+) and partners are willing to commit 40% Aaron / 30% Dave time and €40m capital, T3-C is the right cell. Otherwise, T2-B captures 80% of the risk-adjusted economics at 5% of the capital intensity.

§ 6 · Cross-cutting issues

Five themes that cut across every tier.

Consultant supply, insurer compression, regulatory build, public-pathway floors, and the AI / teledermatology layer. Each is a constraint or opportunity at every tier — the answers differ by scale, but the questions are identical.

§ 6.1

Consultant supply economics

Recruitment funnel spans Type B contract holders, returning diaspora, EU/UK via IMC, CCT trainees. Three named priority Tier-1 candidates per P12: Caoimhe Fahy (Cork), Bryan Murphy (Belfast), Blaithin Moriarty (Kilkenny). SARP gives 30% of income above €75k tax-free for diaspora returnees on 5-year contracts.

Tier 1 sessional€1k–€1.5k/day + share

Tier 2 anchor€275k + 4–6% equity

Tier 3 anchor€300–€350k + equity

SARP relief€105k tax-free / 5y on €250k

§ 6.3

Regulatory build cost (Y1)

Five regulatory touchpoints: IMC (specialist registration), HIQA (mandatory post Patient Safety Bill 2027–2028), HPRA (AI Class IIa MDR €100–€250k), DPC (paediatric photography DPIA), Revenue (Section 110 SPV). EUDAMED Actor Registration was mandatory from 28 May 2026 — already past.

Tier 1€20k–€30k upfront

Tier 2€200k–€400k

Tier 3€500k–€700k

Ongoing opex5–7% of revenue

§ 6.5

NTPF + NI cross-border

NTPF dermatology tender Q3–Q4 2026. AllView €6m HSE framework throughput-constrained — new tender bypasses gatekeeping. NI WLRS £10m fund directs >52-week NI patients to ROI; 49,048 NI dermatology WL with 8,382 waiting more than four years. No ROI provider has dedicated dermatology WLRS pathway — first-mover opportunity.

Tier 1 revenue floor15–25%

Tier 2 revenue floor20–30%

Tier 3 revenue floor25–35%

Drogheda alone€787k–€2.1m / cycle

§ 6.6 + 6.7

Hub-and-spoke + AI layer

Hub-and-spoke shared services breakeven at 3 simultaneous pilots; sweet-spot at 5+. Per-clinic HQ allocation drops €180k → €110–€140k. Schweiger / Forefront / Bupa Health Services template. AI / teledermatology integrates at every tier; HPRA Class IIa MDR (€100–€250k) creates the strategic moat — the AI/data infrastructure criterion is accessible at all tiers, not just institutional.

HQ breakeven3 pilots simultaneous

Sweet spot5+ sites

HPRA Class IIa€100k–€250k

HIQA HTA conclusion"Urgent need to recruit more consultants"

§ 7 · Scoring

All ten cells, ranked. Every sub-score visible.

The Excel companion encodes the formulas. Partners can flex weights and observe sensitivity. Below is the default-weight ranking — the result of the GCCP partner-assumption defaults.

Total score · ranked · default weights (25 / 20 / 15 / 15 / 10 / 10 / 5)

01

T2-B

Tier 2 Cosmetic Boutique + medical mix

78.4

02

T3-B

Tier 3 Cosmetic Premium Hub + Chain

78.2

03

T2-A

Tier 2 Medical Boutique

69.7

04

T1-B

Tier 1 Cosmetic Chambers + 1 Device

68.1

05

T2-C

Tier 2 Surgical (Day-Surgery + TBI)

65.1

06

T1-A

Tier 1 Medical Chambers / Sessional

63.4

07

T1-Net

Tier 1 Network · 10 sites + shared HQ

61.4

08

T3-A

Tier 3 Medical Multi-Site Platform

60.2

09

T3-C

Tier 3 Surgical (Mohs Flagship + Biologics + Paeds)

51.0

10

T1-C

Tier 1 Surgical Chambers / Screening

46.8

Rank	Cell · full name	Profit /25	Scale /20	Cap eff /15	PropCo /15	Cmplx /10	Founder /10	Risk /5	Total
01	T2-B · Cosmetic Boutique + medical mix	15.2	16.0	15.0	15.0	6.7	7.5	3.0	78.4
02	T3-B · Cosmetic Premium Hub + Chain	25.0	13.0	15.0	15.0	4.2	3.8	2.2	78.2
03	T2-A · Medical Boutique	12.3	14.0	15.0	15.0	5.0	6.9	1.5	69.7
04	T1-B · Cosmetic Chambers + 1 Device	11.2	17.0	15.0	4.5	8.3	9.1	3.0	68.1
05	T2-C · Surgical (Day-Surgery + TBI)	13.8	11.0	15.0	15.0	3.3	6.2	0.8	65.1
06	T1-A · Medical Chambers / Sessional	8.2	18.0	15.0	4.5	7.5	8.8	1.5	63.4
07	T1-Net · 10 sites + shared HQ	10.2	19.0	13.6	4.5	5.8	7.5	0.8	61.4
08	T3-A · Multi-Site Medical Platform	22.0	8.0	10.8	15.0	1.7	2.5	0.3	60.2
09	T3-C · Mohs Flagship + Biologics + Paeds	23.9	6.0	5.8	15.0	0.0	0.0	0.3	51.0
10	T1-C · Surgical Chambers / Screening	6.7	12.0	8.7	4.5	5.8	8.4	0.8	46.8

Default weights

T2-B · 78.4

Profit-heavy

T3-B · 88.5

Founder-light

T2-B · 88.7

Scale-heavy

T2-B · 89.4

Risk-averse

T2-B · 84.9

T2-B is the most robust optimal cell across weight variations. Only profit-heavy weighting flips the ranking — and only to T3-B, the runner-up at default weights.

§ 8 · Decision framework · NOT a recommendation

Aaron's seven criteria, mapped against the top six cells.

This section maps the optimal model and runners-up against Aaron's stated 7 investment criteria. It does not pick a tier — that decision is for the partners. The framework is built to make the partner-level decision rigorous and traceable.

Criterion

T2-B

T3-B

T2-A

T1-B

T1-Net

T3-C

1. Operator-led

✓

2. Property-backed

✓ Park Ave

✓ Flagship

✓ Park Ave

✗ Lease

✗ Lease only

✓ Multi-site

3. Monthly cash flow Y1

⚠ Y2

⚠ Y1.5

✗ Y3+

4. Operable by someone else

✓ Anchor + RANP

⚠ Platform CEO

✓ Anchor + assoc

✓ Operator-led

⚠ HQ team

✗ Founder-intensive

5. Deal flow / credibility

✓ Healthcare CRE

✓ Brand platform

✓ Medical credibility

⚠ Cosmetic-narrow

✓ Multi-region

✓ Apex platform

6. Capped downside (€300k)

✗ Capex €2m

✗ Capex €15m

✗ Capex €1.8m

⚠ €400k mid (€150k OK)

✗ Capex €3.75m

✗ Capex €40m

7. AI / data infrastructure

✓ HPRA Class IIa

✓ Platform tech

✓ AI triage

⚠ Optional

✓ HQ tech stack

✓ Apex AI

Critical observation · Criterion #6

Strict interpretation eliminates every cell except T1-B at the chambers low-end. If the €300k cap is binding, the optimal-by-score model (T2-B at €2m capex) is not pursuable directly. The right interpretation depends on whether €300k is (a) the total GCCP commitment cap → only T1 chambers viable; (b) the Phase-1 sponsor cap with subsequent phases LP-funded → migration paths apply; or (c) the criterion the v1.5 plan was designed against — in which case v1.5 / DCF v2.0 thinking applies, not this matrix.

Partner objective routing

The decision the partners now make is about strategic objective — what do you want this platform to be? Each route below maps directly to a recommended cell.

If LP fund product (€20m+ raise · 5y exit)

T3-B or T2-A migration

Premium hub + chain captures multi-site exit value at €92m mid; T2-A migration adds the medical-pathway credibility for institutional FOs. Insurer-strategic exit at 14× achievable.

If capital-light prove-it then decide

T1-B / T1-Network · Path A or B

Single T1-B chambers or T1-Network of 3–5 sites at €3.75m. Y2 KPI gate before Tier 2 migration. Mirrors HRBR / Beacon Face & Dermatology origin path.

If multi-billion PE exit at apex

T3-C — Mohs flagship

Only viable cell for insurer-strategic 14× exit (Bridgepoint→Oasis→Bupa template). €40m capex, 40% Aaron / 30% Dave, 18–30 month breakeven. Highest absolute return at worst risk-adjusted.

If balanced risk-return without LP

T2-B — Cosmetic Boutique with medical mix

The optimal-by-score answer. €2m capex (Park Avenue freehold path adds €5–6m). Aaron + Dave 4 days/month. LP-fundable at €5–8m equity raise. €1.91m Y5 EBITDA at 33% margin. €20.1m Y5 EV.

§ 9 · Migration paths

Three routes between the tiers — over three to five years.

The optimal-model finding does not preclude tier migration. The data supports a clean Tier 1 → Tier 2 → Tier 3 sequence; jumping straight to Tier 3 is not supportable given consultant-supply binding and founder-time burn unless the partners commit explicitly.

Path A · Recommended

T2-B-led

Open T2-B Park Avenue Year 1. Y3 EBITDA milestone €1.5m → open second T2-B / T2-A site Year 4. Year 5 → consider T3-B premium hub + chain expansion.

T2-B → T2 #2 → T3-B

Path B · Conservative

T1-led

Open single T1-B (cosmetic chambers) Year 1 at sub-€500k. Y2 KPI gate → expand to T1-Network (3–5 sites). Year 4 → consider migration to T2-B based on platform performance.

T1-B → T1-Net → T2-B

Path C · Ambitious

T3-C direct

Direct institutional Mohs flagship Year 1 — only if partners commit 40% Aaron / 30% Dave time, €40m capital, and Tier-1 anchor consultants pre-recruited. Insurer-strategic 14× exit at the apex.

T3-C → €100m+ exit

§ 10 · Brand concepts

Four worlds, mapped to three tiers.

Each tier has a footprint, an economics envelope, and a customer. It also has a feeling. Below: four brand territories developed in parallel — Cló, Helix, Maison Derm, Halo — each mapped to the tier it most naturally fits, and the cell it most directly serves. The territory chosen at selection becomes the world the customer walks into; the tier sets the scale.

Tier 1 · Small premises

Heritage chambers, or high-street habit.

€100k–€1m · 500–1,500 sqft · 3–4 FTE

A single suite calls for an unambiguous brand position. Either you're the discreet practice on Merrion Square — by introduction, no signage — or you're the visible storefront people walk past every Saturday. Anything in between reads weak at this scale.

Brand 01 T1-A · T1-B

Cló

Skin, perfected in Ireland.

A Georgian-Dublin private practice, by introduction. Brass plate, fountain pen, cream linen-bound consultation files. Best fit for chambers within Merrion Square / Fitzwilliam / Mountjoy. Charges premium per consultation; declines insurer participating where the brand commands self-pay. Recruits the named anchor consultant the brand was built around.

Heritage Luxury By introduction

Brand 04 T1-B

HAL

Confidence, made simple.

A high-footfall storefront on Camden St / Wexford St / Drury St. White oak, terrazzo, navy-and-coral. Members'-priced facials at €85, transparent pricing, pickup window for products. Best fit for the chain-replicable T1-B cosmetic chambers + 1 device, with a clear path to T1-Network of 5–10 sites. Optimised for repeat-visit economics.

Optimistic Wellness Members from €85/mo

Tier 2 · Medium boutique · Optimal cell

Editorial house, or measured studio.

€500k–€4m · 2,500–4,000 sqft · 10–14 FTE

The optimal cell by score (T2-B at 78.4) sits here. Two brands compete for the boutique — one edits like a magazine and runs like a hotel; the other measures like a lab and feels like a Trinity research building. Both are credible institutional LP products at €2m capex.

Brand 03 T2-B · OPTIMAL

MAISONDERM

Where dermatology meets style.

A converted 19th-century commercial building, hotel-lobby polish at 7pm. Oxblood leather, smoked glass, patinated brass, terrazzo. Direct fit for T2-B Cosmetic Boutique with medical mix — the optimal cell by score (78.4 / 100). Members'-coded for the highest-LTV cohort. Quarterly issue magazine. Cadogan Clinic Chelsea is the international comp.

Editorial Cosmopolitan Members from €240/mo

Brand 02 T2-A · T2-B

HELIX

Personalised skin science, in real time.

A modern boutique with the imaging suite as the visual anchor. Anodised aluminium, glass, white thermoplastic. Patient skin-mapped at every visit. Strong fit for T2-A Medical Boutique or a measurement-led variant of T2-B — earns the AI-data-infrastructure criterion immediately. Speaks to the Trinity / RCSI / Stripe / Intercom Dublin demographic.

Tech-Clinical Future Plan within 24 hours

Tier 3 · State-of-the-art flagship

Apex science, or apex hospitality.

€8m–€50m+ · 8,000–16,000 sqft · 45–60 FTE

At flagship scale the brand defines the whole institution. Helix scales because it was system-native from the start — the imaging suite as atrium reads bigger, not weaker. Maison Derm scales because hotel-lobby grammar runs at any footprint, from a single members' lounge to a full premium hub + chain.

Brand 02 T3-C · T3-A

HELIX

Skin, measured. At every scale.

At flagship scale Helix earns its institutional reading. The full-spectrum imaging suite becomes the atrium hero. The data-publication promise becomes a quarterly outcomes report. Best fit for T3-C Mohs flagship + biologics + paediatric — the institutional gold standard, where measurement-led practice is the strongest moat against insurer rate compression. The Apple-keynote material language scales without losing distinctiveness at site five.

Tech-Clinical · Apex Insurer-strategic 14× exit

Brand 03 T3-B

MAISONDERM

A house, openly. At hub-and-satellite scale.

The hotel-lobby grammar runs at any footprint. A flagship with the full editorial polish, four to six satellite cosmetic clinics in the same hand. Direct fit for T3-B Cosmetic Premium Hub + Skin Clinics Chain — runner-up overall (78.2) and highest absolute Y5 EBITDA in the matrix at €7.7m. Members'-coded across the network; the brand is the cross-sell engine between hub and satellites.

Editorial · Hub + Chain Y5 EV €92m mid

The four-by-three brand-fit matrix.

A summary view: which brand serves which tier, with the cell-code recommendation. Primary fits in brass; secondary fits in grey; non-fits muted. The brand chosen at selection becomes the world the customer walks into — the tier sets the scale of that world.

Cló

HELIX

MAISON
DERM

HAL

Tier 1
Small premises

PrimaryT1-A · T1-B

— —Tech-clinical reads
oversized at chambers scale

— —Editorial reads
oversized at chambers scale

PrimaryT1-B

Tier 2
Medium boutique

StretchT2-A heritage variant

PrimaryT2-A · T2-B

Primary · OptimalT2-B · 78.4

StretchT2-B as members
+ retail at upper end

Tier 3
Flagship

— —Heritage doesn't
scale to multi-site

PrimaryT3-C · T3-A

PrimaryT3-B · 78.2

— —Habit-led brand reads
thin at flagship scale

Reading the matrix

Two brands cover the full spectrum: HELIX works at Tier 2 and Tier 3 — system-native, scalable, defensible at site five. MAISON DERM also works at Tier 2 and Tier 3 — editorial grammar holds at hub-and-satellite scale. CLÓ is a Tier 1 brand at heart; pushed to Tier 2 it becomes a heritage variant, but the chambers logic is its strongest reading. HALO is a Tier 1 / Tier 1-Network brand — habit-led, repeat-visit, transparent — and reads thin at institutional scale. If GCCP commits to Path A (T2-B-led with T3-B at year five), MAISON DERM is the brand candidate the path was built for. If the optimisation is measurement-and-data, HELIX. If chambers-only, CLÓ or HALO depending on whether the customer is established (CLÓ) or habit-led (HALO).

The complete operating spectrum.

A market mapped end-to-end — from sole-consultant chambers to multi-billion institutional flagship.

Cosmetic dominates the scoring at every tier.

Consultant supply is the binding constraint at every tier.

Scoring is a guide, not a recommendation.

Three tiers × three clinical divisions = nine cells.

Tier 2 Cosmetic Boutique with medical mix

Tier 3 Cosmetic Premium Hub + Skin-Clinics Chain

Tier 2 Medical Boutique

Demand is structurally large and growing on every measurable axis.

Demand structure

Supply structure — the binding constraint.

Insurer landscape · three scenarios.

Base — VHI matches Laya cap by Y2.

Adverse — procedure-bundled rates by Y2–3.

Severe — single dominant rate-setter at €110.

Public-pathway revenue floors.

Three operating tiers — and how to read them.

Entry-Level Operations

Mid-Level Boutique

Institutional Flagship

Small premises.

Chambers · sessional consultant

Chambers + 1 device

Screening only · no Mohs

10× Tier 1 sites + Dublin shared services hub

Medium boutique.

Boutique medical-led

Boutique cosmetic + medical mix

Day-surgery + TBI · no Mohs

State-of-the-art flagship.

Multi-site GP-referrer platform

Premium hub + skin-clinics chain

Mohs flagship + biologics + paeds

Five themes that cut across every tier.

Consultant supply economics

Regulatory build cost (Y1)

NTPF + NI cross-border

Hub-and-spoke + AI layer

All ten cells, ranked. Every sub-score visible.

Total score · ranked · default weights (25 / 20 / 15 / 15 / 10 / 10 / 5)

Aaron's seven criteria, mapped against the top six cells.

Partner objective routing

T3-B or T2-A migration

T1-B / T1-Network · Path A or B

T3-C — Mohs flagship

T2-B — Cosmetic Boutique with medical mix

Three routes between the tiers — over three to five years.

T2-B-led

T1-led

T3-C direct

Four worlds, mapped to three tiers.

Heritage chambers, or high-street habit.

Editorial house, or measured studio.

Apex science, or apex hospitality.

The four-by-three brand-fit matrix.

The decision now is about strategic objective.